Αποτελέσματα Αναζήτησης
5-year relative survival rates for GIST. These numbers are based on people diagnosed with GIST [small intestine, esophagus, colon, rectum, peritoneum, stomach, omentum] between 2012 and 2018.
8 Απρ 2021 · Early stage GIST may be curable, but there is a risk of recurrence. The overall relative 5-year survival rate for GIST is 83 percent, but this varies by stage and other factors. Newer...
24 Αυγ 2023 · Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin. GIST spans a wide clinical spectrum that ranges from tumors with essentially no metastatic potential to malignant and life-threatening spread diseases.
5 Ιουν 2024 · Gastric GISTs have a better prognosis than small bowel or rectal GISTs. Tumour rupture through a serosal surface is an adverse prognostic factor and should be recorded, whether it took place...
27 Απρ 2023 · GISTs can happen in people at any age, but they are most common in adults and very rare in children. The cause of most GIST s isn't known. A small number are caused by genes passed from parents to children.
11 Απρ 2023 · Most GISTs harbor characteristic mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA), while mutations in succinate dehydrogenase (SDH) or other genes are less frequent. The clinical presentation, diagnosis, and prognosis of GISTs will be discussed here.
26 Σεπ 2022 · Gastrointestinal stromal tumors (GISTs) are typically benign tumors that most commonly occur in the gastrointestinal (GI) tract. While only comprising 0.1% to 3% of all GI malignancies, these tumors are the most common mesenchymal tumors of the GI tract.
